Clinical trialsCompany release

Helus Pharma's HLP003 meets primary endpoint in Phase 3 APPROACH depression trial

Helus Pharma Inc. (HELP) · Mon 16 Nov 2026

Topline data show the deuterated psilocin candidate improved MADRS scores versus placebo as adjunctive therapy in adults with major depressive disorder, with a second pivotal readout due in Q4 2027.

Helus Pharma reported on 16 November 2026 that HLP003, its deuterated psilocin candidate, met the primary endpoint in the Phase 3 APPROACH trial. The study tested the product as an adjunctive treatment in adults with major depressive disorder (MDD).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Helus Pharma Inc. ↗

Article written by VigiEye from the official source (Helus Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →